Hydrocortisone

Generic Name: Hydrocortisone

Brand Names: Ala-cort, Ala-scalp, Alcortin, Alkindi, Anusol HC, Aquanil HC, Casporyn HC, Cipro, Cipro HC, Colocort, Cortaid, Cortane-B, Cortef, Cortenema, Cortisporin, Cortizone-10, Dermacort, Dermarest Eczema, Dermazene, Home Papkit, Hydroskin, Monistat Itch Relief, Neosporin Eczema, Preparation H Hydrocortisone, Procto-med, Procto-pak, Proctocort, Proctol, Proctosedyl, Proctosol, Proctozone HC, Scalpicin Itch Relief, Texacort, Vanoxide-HC, Xerese, Plenadren, Efmody

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₅

CAS Number: 50-23-7

Unique Ingredient Identifier: WI4X0X7BPJ

Background: Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions. It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone.

Hydrocortisone was granted FDA approval on 5 August 1952.

Indication: Otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammation. Hydrocortisone tablets are indicated for certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions. A hydrocortisone enema is indicated for ulcerative colitis, a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infections, and a topical cream with acyclovir is indicated to treat cold sores. Oral granules of hydrocortisone are used as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Adrenal Insufficiency, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Crohn's Disease (CD), Dermatitis, Dermatomyositis (DM), Dermatosis, Drug hypersensitivity reaction, Epicondylitis, Erythroblastopenia, Fissure;Anal, Haemorrhoids, Herpes Labialis, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Infection of the Fenestration Cavity, Infection of the Mastoidectomy Cavity, Iridocyclitis, Iritis, Itching caused by Hemorrhoids, Itching of the Anus, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Lymphomas NEC, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Hemorrhoids, Pemphigus, Posterior Uveitis, Posttraumatic Osteoarthritis, Primary adrenocortical insufficiency, Proctitis, Proteinuria, Pruritis of the skin, Psoriatic Arthritis, Rectal inflammations NEC, Rheumatic heart disease, unspecified, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Skin Diseases, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Tenosynovitis, Acute rheumatic carditis, Anterior eye segment inflammation, Cryptitis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Non-suppurative Thyroiditis, Severe Erythema multiforme, Severe Psoriasis, Subacute Bursitis, Superficial infection of the external auditory canal with inflammation, Symptomatic Sarcoidosis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Phase 2

Terminated

Conditions: Acute Lymphocytic Leukemia
Adult Lymphoblastic Lymphoma

Interventions: Drug: DNR
Drug: VCR
Drug: PEG-asp
Drug: CTX
Drug: Prednisone
Drug: Liposomal AraC
Drug: MTX
Drug: LCV
Drug: AraC
Drug: Etoposide
Drug: Dasatinib
Drug: Rituximab
Drug: Hydrocortisone

First Posted Date: 2014-01-23

Last Posted Date: 2022-05-02

Lead Sponsor: University of California, San Diego

Target Recruit Count: 31

Registration Number: NCT02043587

Locations: 🇺🇸
UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center, La Jolla, California, United States
🇺🇸
Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 1 locations

Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study

Phase 4

Completed

Conditions: Shock

Interventions: Other: Placebo
Drug: Hydrocortisone

First Posted Date: 2014-01-23

Last Posted Date: 2019-03-26

Lead Sponsor: Children's Hospital of Eastern Ontario

Target Recruit Count: 57

Registration Number: NCT02044159

Locations: 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
🇨🇦
Hospital St. Justine, Montreal, Quebec, Canada
🇨🇦
McMaster Children's Hospital, Hamilton, Ontario, Canada

and more 4 locations

Hydrocortisone for Term Hypotension

Phase 3

Completed

Conditions: Infant, Newborn, Diseases
Cardiovascular Insufficiency

Interventions: Drug: Placebo
Drug: Hydrocortisone

First Posted Date: 2013-10-01

Last Posted Date: 2021-07-06

Lead Sponsor: NICHD Neonatal Research Network

Target Recruit Count: 12

Registration Number: NCT01954056

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States

and more 15 locations

Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure

Phase 2

Conditions: Addison Disease

Interventions: Drug: Hydrocortisone

First Posted Date: 2013-05-07

Last Posted Date: 2013-12-02

Lead Sponsor: Haukeland University Hospital

Target Recruit Count: 20

Registration Number: NCT01847690

Locations: 🇳🇴
Haukeland Universitetessykehus, Department of Medicine, Bergen, Norway

Vilazodone for Corticosteroid-Induced Memory Impairment

Phase 2

Completed

Conditions: Memory Impairment

Interventions: Drug: Vilazodone
Drug: Placebo
Drug: Hydrocortisone

First Posted Date: 2013-04-10

Last Posted Date: 2019-04-11

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 24

Registration Number: NCT01828515

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty

Phase 4

Completed

Conditions: Total Knee Arthroplasty

Interventions: Drug: Placebo
Drug: Hydrocortisone

First Posted Date: 2013-03-21

Last Posted Date: 2022-04-14

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 60

Registration Number: NCT01815918

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

Effect of Steroids on Thrombosis (Blood Clot Formation) and Inflammation in Patients Undergoing Hip Surgery

Not Applicable

Completed

Conditions: Total Hip Replacement

Interventions: Drug: Placebo (for Prednisone)
Drug: Prednisone
Drug: Hydrocortisone

First Posted Date: 2013-02-04

Last Posted Date: 2017-01-05

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 40

Registration Number: NCT01782859

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia

Phase 2

Conditions: Adrenal Hyperplasia, Congenital

Interventions: Drug: Hydrocortisone
Drug: Cortisone acetate

First Posted Date: 2013-01-18

Last Posted Date: 2016-12-21

Lead Sponsor: Haukeland University Hospital

Target Recruit Count: 20

Registration Number: NCT01771328

Locations: 🇳🇴
Haukeland Universitetssykehus, Department of Medicine, Bergen, Norway

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration

Completed

Conditions: Anxiety Disorders
Major Depressive Disorder

Interventions: Drug: Hydrocortisone

First Posted Date: 2012-10-19

Last Posted Date: 2015-03-20

Lead Sponsor: University of Texas at Austin

Target Recruit Count: 120

Registration Number: NCT01710202

Locations: 🇺🇸
University of Texas at Austin Department of Psychology, Austin, Texas, United States
🇺🇸
University of Texas at Austin, Austin, Texas, United States

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Phase 1

Completed

Conditions: Lymphoblastic Leukemia, Acute, Childhood
Peripheral T-cell Lymphoma
Lymphoblastic Lymphoma

Interventions: Drug: Temsirolimus
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Cytarabine

First Posted Date: 2012-06-07

Last Posted Date: 2023-07-27

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 16

Registration Number: NCT01614197

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States
🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States

and more 29 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy